Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Gastrointestinal therapies developer files shelf registration statement
June 6th, 2005
Santarus, Inc. (SNTS), a company focused on therapies for gastrointestinal diseases and disorders, announced it has filed with the U.S. Securities and Exchange Commission (SEC) a shelf registration statement on form S-3 which, when declared effective, will permit Santarus, from time to time, to offer and sell up to $75 million of debt or equity securities. The company believes a shelf registration, which has become a common financing tool in the healthcare industry, will give it greater flexibility as it finances its business in the future. Santarus plans to use the proceeds from any offerings under this registration statement to support sales and...
Source: Biotech Business Week (2005-06-06)
|
